Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158990 · ClinicalTrials.gov registry record · Phase 3
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
A Phase 3 study of Bipolar Disorder and Major Depression, sponsored by Hadassah Medical Organization.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 2
- Study locations
NCT00158990 is a Phase 3 study of Bipolar Disorder and Major Depression that has completed, run by Hadassah Medical Organization. The registered enrollment target is 220 participants, below the 331-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (34% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00158990, a Phase 3 study of Bipolar Disorder and Major Depression, has completed, sponsored by Hadassah Medical Organization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this project is to determine whether concurrent treatment of patients with major depression (unipolar or bipolar) with triiodothyronine (T3) and sertraline, will lead to a stronger and/or more rapid antidepressant effect than treatment with sertraline alone.
Conditions Studied
Interventions
- DRUG sertraline
- DRUG triiodothyronine
Study Locations (2)
New Jersey
- Global Medical Institutes - Princeton
Other
- Hadassah Medical Organisation - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2002-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158990
The ClinicalTrials.gov registry entry for NCT00158990 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (34% lower). The listed sponsor is Hadassah Medical Organization, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which sertraline is the first listed.
NCT00158990 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00158990 about?
NCT00158990 is a clinical study titled "Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.". The purpose of this project is to determine whether concurrent treatment of patients with major depression (unipolar or bipolar) with triiodothyronine (T3) and sertraline, will lead to a stronger and/or more rapid antidepressant effect than treatment with sertraline alone.
What is the current status of trial NCT00158990?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2002-10. Estimated completion is 2007-07.
What conditions does trial NCT00158990 study?
This clinical trial studies the following conditions: Bipolar Disorder, Major Depression, Unipolar Depression.
What interventions are being tested in trial NCT00158990?
The interventions under investigation include: sertraline (DRUG), triiodothyronine (DRUG).
Who is sponsoring clinical trial NCT00158990?
This trial is sponsored by Hadassah Medical Organization, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00158990 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RECRUITING · Phase 3
-
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
COMPLETED · Phase 3
-
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
COMPLETED · Phase 3
-
Acute Treatment of Bipolar II Depression
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.